US20040037828A1 - Methods and pharmaceutical compositions for healing wounds - Google Patents

Methods and pharmaceutical compositions for healing wounds Download PDF

Info

Publication number
US20040037828A1
US20040037828A1 US10/644,775 US64477503A US2004037828A1 US 20040037828 A1 US20040037828 A1 US 20040037828A1 US 64477503 A US64477503 A US 64477503A US 2004037828 A1 US2004037828 A1 US 2004037828A1
Authority
US
United States
Prior art keywords
insulin
cells
pharmaceutical composition
pkc
skin wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/644,775
Other languages
English (en)
Inventor
Tamar Tennenbaum
Sanford Sampson
Toshio Kuroki
Addy Alt
Shlomzion Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bar Ilan University
Original Assignee
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/169,801 external-priority patent/US7402571B2/en
Application filed by Bar Ilan University filed Critical Bar Ilan University
Priority to US10/644,775 priority Critical patent/US20040037828A1/en
Assigned to BAR-ILAN UNIVERSITY reassignment BAR-ILAN UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALT, ADDY, SAMPSON, SANFORD, SHEN, SHLOMZION, KUROKI, TOSHIO, TENNENBAUM, TAMAR
Publication of US20040037828A1 publication Critical patent/US20040037828A1/en
Priority to NZ573737A priority patent/NZ573737A/en
Priority to CN200910217138A priority patent/CN101850108A/zh
Priority to AU2004257485A priority patent/AU2004257485B2/en
Priority to PCT/IL2004/000640 priority patent/WO2005007072A2/fr
Priority to RU2008138474/14A priority patent/RU2392959C1/ru
Priority to CA002532352A priority patent/CA2532352A1/fr
Priority to EP12004249.4A priority patent/EP2540301A3/fr
Priority to NZ545318A priority patent/NZ545318A/en
Priority to RU2010130763/15A priority patent/RU2491952C2/ru
Priority to CN2004800265295A priority patent/CN1852722B/zh
Priority to EP12004250A priority patent/EP2526953A1/fr
Priority to RU2006104617/14A priority patent/RU2359694C2/ru
Priority to EP12004247A priority patent/EP2526952A1/fr
Priority to EP04744980.6A priority patent/EP1648474B1/fr
Priority to JP2006520104A priority patent/JP4790609B2/ja
Priority to EP12004248A priority patent/EP2540302A1/fr
Priority to NZ588743A priority patent/NZ588743A/xx
Priority to CN201310452225.6A priority patent/CN103751211A/zh
Priority to IL173148A priority patent/IL173148A/en
Priority to US11/332,774 priority patent/US20060258562A1/en
Priority to HK06111616.5A priority patent/HK1090843A1/xx
Priority to US12/120,954 priority patent/US20080280816A1/en
Priority to RU2008138473/14A priority patent/RU2404799C2/ru
Priority to US12/404,622 priority patent/US8093211B2/en
Priority to AU2009225335A priority patent/AU2009225335B2/en
Priority to US12/693,968 priority patent/US20100129332A1/en
Priority to JP2010285810A priority patent/JP2011057711A/ja
Priority to JP2010285808A priority patent/JP2011057709A/ja
Priority to JP2010285809A priority patent/JP2011057710A/ja
Priority to US13/311,675 priority patent/US20120076764A1/en
Priority to IL221624A priority patent/IL221624A0/en
Priority to JP2013113603A priority patent/JP5852051B2/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
US10/644,775 2000-07-31 2003-08-21 Methods and pharmaceutical compositions for healing wounds Abandoned US20040037828A1 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
US10/644,775 US20040037828A1 (en) 2002-07-09 2003-08-21 Methods and pharmaceutical compositions for healing wounds
NZ588743A NZ588743A (en) 2003-07-15 2004-07-15 Use of a protein kinase C (PKC) alpha inhibitor for treating inflammation of the skin
EP12004248A EP2540302A1 (fr) 2003-07-15 2004-07-15 Procédés et compositions pharmaceutiques servant à guérir des blessures
CN2004800265295A CN1852722B (zh) 2003-07-15 2004-07-15 胰岛素和十四酰化PKCα伪底物用于制备皮肤创伤愈合的药物组合物的用途
EP04744980.6A EP1648474B1 (fr) 2003-07-15 2004-07-15 Compositions pharmaceutiques pour cicatriser des lesions
CN201310452225.6A CN103751211A (zh) 2003-07-15 2004-07-15 用于愈合创伤的方法和药物组合物
AU2004257485A AU2004257485B2 (en) 2003-07-15 2004-07-15 Methods and pharmaceutical compositions for healing wounds
PCT/IL2004/000640 WO2005007072A2 (fr) 2003-07-15 2004-07-15 Methodes et compositions pharmaceutiques pour cicatriser des lesions
RU2008138474/14A RU2392959C1 (ru) 2003-07-15 2004-07-15 Способы и фармакологические композиции для заживления ран
CA002532352A CA2532352A1 (fr) 2003-07-15 2004-07-15 Methodes et compositions pharmaceutiques pour cicatriser des lesions
EP12004249.4A EP2540301A3 (fr) 2003-07-15 2004-07-15 Procédés et compositions pharmaceutiques servant à guérir des blessures
NZ545318A NZ545318A (en) 2003-07-15 2004-07-15 Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor
RU2010130763/15A RU2491952C2 (ru) 2003-07-15 2004-07-15 Способы и фармакологические композиции для заживления ран
CN200910217138A CN101850108A (zh) 2003-07-15 2004-07-15 用于愈合创伤的方法和药物组合物
EP12004250A EP2526953A1 (fr) 2003-07-15 2004-07-15 Procédés et compositions pharmaceutiques servant à guérir des blessures
RU2006104617/14A RU2359694C2 (ru) 2003-07-15 2004-07-15 Способы и фармакологические композиции для заживления ран
EP12004247A EP2526952A1 (fr) 2003-07-15 2004-07-15 Procédés et compositions pharmaceutiques servant à guérir des blessures
NZ573737A NZ573737A (en) 2003-07-15 2004-07-15 Methods and pharmaceutical compositions for healing wounds comprising a PKC modulator
JP2006520104A JP4790609B2 (ja) 2003-07-15 2004-07-15 創傷治癒のための方法及び薬剤組成物
IL173148A IL173148A (en) 2003-07-15 2006-01-15 Use of insulin for the preparation of pharmaceutical compositions for healing wounds
US11/332,774 US20060258562A1 (en) 2000-07-31 2006-01-17 Methods and pharmaceutical compositions for healing wounds
HK06111616.5A HK1090843A1 (en) 2003-07-15 2006-10-20 Pharmaceutical compositions for healing wounds
US12/120,954 US20080280816A1 (en) 2001-07-23 2008-05-15 Methods and pharmaceutical compositions for healing wounds
RU2008138473/14A RU2404799C2 (ru) 2003-07-15 2008-09-29 Способы и фармакологические композиции для заживления ран
US12/404,622 US8093211B2 (en) 2000-07-31 2009-03-16 Methods and pharmaceutical compositions for healing wounds
AU2009225335A AU2009225335B2 (en) 2003-07-15 2009-10-14 Methods and pharmaceutical compositions for healing wounds
US12/693,968 US20100129332A1 (en) 2000-07-31 2010-01-26 Methods and pharmaceutical compositions for healing wounds
JP2010285810A JP2011057711A (ja) 2003-07-15 2010-12-22 創傷治癒のための方法及び薬剤組成物
JP2010285808A JP2011057709A (ja) 2003-07-15 2010-12-22 創傷治癒のための方法及び薬剤組成物
JP2010285809A JP2011057710A (ja) 2003-07-15 2010-12-22 創傷治癒のための方法及び薬剤組成物
US13/311,675 US20120076764A1 (en) 2001-07-23 2011-12-06 Methods and pharmaceutical compositions for healing wounds
IL221624A IL221624A0 (en) 2003-07-15 2012-08-23 Methods and pharmaceutical compositions for healing wounds
JP2013113603A JP5852051B2 (ja) 2003-07-15 2013-05-30 創傷治癒のための方法及び薬剤組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/169,801 US7402571B2 (en) 2000-07-31 2001-07-23 Methods and pharmaceutical compositions for healing wounds
US48690603P 2003-07-15 2003-07-15
US10/644,775 US20040037828A1 (en) 2002-07-09 2003-08-21 Methods and pharmaceutical compositions for healing wounds

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US10169801 Continuation-In-Part 2001-07-23
PCT/IL2001/000675 Continuation-In-Part WO2002009639A2 (fr) 2000-07-31 2001-07-23 Methodes et compositions pharmaceutiques de cicatrisation de lesions
US10/169,801 Continuation-In-Part US7402571B2 (en) 2000-07-31 2001-07-23 Methods and pharmaceutical compositions for healing wounds

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/332,774 Continuation-In-Part US20060258562A1 (en) 2000-07-31 2006-01-17 Methods and pharmaceutical compositions for healing wounds
US12/120,954 Continuation US20080280816A1 (en) 2001-07-23 2008-05-15 Methods and pharmaceutical compositions for healing wounds
US12/404,622 Continuation US8093211B2 (en) 2000-07-31 2009-03-16 Methods and pharmaceutical compositions for healing wounds

Publications (1)

Publication Number Publication Date
US20040037828A1 true US20040037828A1 (en) 2004-02-26

Family

ID=34083396

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/644,775 Abandoned US20040037828A1 (en) 2000-07-31 2003-08-21 Methods and pharmaceutical compositions for healing wounds
US12/120,954 Abandoned US20080280816A1 (en) 2001-07-23 2008-05-15 Methods and pharmaceutical compositions for healing wounds
US12/404,622 Expired - Lifetime US8093211B2 (en) 2000-07-31 2009-03-16 Methods and pharmaceutical compositions for healing wounds
US13/311,675 Abandoned US20120076764A1 (en) 2001-07-23 2011-12-06 Methods and pharmaceutical compositions for healing wounds

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/120,954 Abandoned US20080280816A1 (en) 2001-07-23 2008-05-15 Methods and pharmaceutical compositions for healing wounds
US12/404,622 Expired - Lifetime US8093211B2 (en) 2000-07-31 2009-03-16 Methods and pharmaceutical compositions for healing wounds
US13/311,675 Abandoned US20120076764A1 (en) 2001-07-23 2011-12-06 Methods and pharmaceutical compositions for healing wounds

Country Status (9)

Country Link
US (4) US20040037828A1 (fr)
EP (5) EP2526952A1 (fr)
JP (1) JP5852051B2 (fr)
CN (1) CN103751211A (fr)
AU (2) AU2004257485B2 (fr)
CA (1) CA2532352A1 (fr)
HK (1) HK1090843A1 (fr)
RU (2) RU2359694C2 (fr)
WO (1) WO2005007072A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100062048A1 (en) * 2006-05-02 2010-03-11 University Of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
US20110021422A1 (en) * 2005-08-29 2011-01-27 Tamar Tennenbaum Method and compositions for prevention and treatment of diabetic and aged skin
US8349793B2 (en) 2010-01-11 2013-01-08 Heal0r, Ltd. Method for treatment of inflammatory disease and disorder
US8507431B2 (en) 2003-08-07 2013-08-13 Healor Ltd. Methods for accelerating wound healing by administration of a preadipocyte modulator or an adipocyte modulator
WO2017053659A1 (fr) * 2015-09-23 2017-03-30 Khan Tapan K Méthodes pour la survie et la régénération de fibroblastes du derme à l'aide d'activateurs de la pkc
US11419830B2 (en) 2017-05-17 2022-08-23 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP1383540B1 (fr) 2000-07-31 2009-04-29 Bar-Ilan University Methodes et compositions pharmaceutiques de cicatrisation de lesions
US20050129776A1 (en) * 2002-05-03 2005-06-16 Inserm Microparticles supporting cells and active substances
WO2009108890A1 (fr) 2008-02-27 2009-09-03 Biomet Biologics, Llc Procédés et compositions pour administrer un antagoniste de récepteur d’interleukine-1 antagonist
WO2012070967A1 (fr) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Composition pharmaceutique à action cicatrisante, anti-brûlures, régénérante et antivirale destinée à l'application locale
US10292997B2 (en) 2011-01-17 2019-05-21 Daniel N. Rastein Compositions and methods for stimulating wound healing
US10143725B2 (en) * 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
EP3011959A1 (fr) 2014-10-23 2016-04-27 Santen SAS Composé d'ammonium quaternaire destiné à être utilisé en tant qu'inhibiteur de la protéine kinase C alpha
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
DK3538132T3 (da) 2016-11-14 2021-04-06 Univ Copenhagen Rektalt insulin til behandling af inflammatoriske tarmsygdomme
MX2020004251A (es) 2017-10-19 2021-05-27 Mona E Buice Composición tópica para cicatrización mejorada de heridas abiertas.
CN114323894A (zh) * 2021-12-20 2022-04-12 南京美新诺医药科技有限公司 一种组织中的药物分析方法

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
US4940660A (en) * 1985-11-25 1990-07-10 Wako Pure Chemical Industries Color developing method in clinical examinations
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5461030A (en) * 1991-02-01 1995-10-24 Life Medical Science, Inc. Compositions and methods for enhancing wound healing
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5770228A (en) * 1991-11-04 1998-06-23 Zymogenetics, Inc. Platelet derived growth factor gel formulation
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US5942487A (en) * 1996-11-29 1999-08-24 Senju Pharmaceutical Co., Ltd. Composition for treating cornea
US6319907B1 (en) * 1997-02-13 2001-11-20 Renovo Limited Wound healing
US6489306B2 (en) * 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6582713B2 (en) * 2000-04-06 2003-06-24 Univ. Of Colorado - Colorado Springs Compositions and methods for promoting wound healing
US6737241B2 (en) * 1996-01-23 2004-05-18 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US6841472B2 (en) * 2000-12-26 2005-01-11 Nec Electronics Corporation Semiconductor device and method of fabricating the same
US20050054608A1 (en) * 2000-11-29 2005-03-10 Claire Linge Method of preventing or reducing scarring of human skin

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1447701A (en) 1919-10-02 1923-03-06 Anchor Cap & Closure Corp Apparatus for indicating pressure conditions in sealed containers
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4558033A (en) 1983-06-06 1985-12-10 Amgen Potentiation of the effects of insulin by peptides
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
EP0178321A1 (fr) 1984-04-30 1986-04-23 The Trustees Of Columbia University In The City Of New York Traitement topique du diabete a l'aide d'insuline et d'un agent ameliorant la penetration applique sur la peau et recouvert d'une pastille
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
JPH0739508B2 (ja) 1986-11-11 1995-05-01 株式会社林原生物化学研究所 プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
ATE132266T1 (de) 1987-05-01 1996-01-15 Stratagene Inc Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten
JPS63303929A (ja) 1987-06-04 1988-12-12 Kanji Izumi 創傷治療剤
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5700450A (en) 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
ZA892928B (en) 1988-04-25 1991-01-30 Pro Neuron Inc Pharmaceutical compositions containing deoxyribonucleosides for wound healing
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5137734A (en) 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5158935A (en) 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5423778A (en) 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
EP0647268B1 (fr) 1990-06-15 2004-03-03 Scios Inc. Mammifere transgenique non humain presentant la pathologie de formation d'amyloides de la maladie d'alzheimer
US5288846A (en) 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
EP0508792A1 (fr) 1991-04-11 1992-10-14 Schering Corporation Agents antitumoraux et antipsoriasis
EP0580778B1 (fr) 1991-04-19 1999-08-11 LDS Technologies, Inc. Formulations de microemulsions a inversion de phase
JPH0543453A (ja) 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
WO1993014200A1 (fr) 1992-01-07 1993-07-22 Tsi Corporation Modeles d'animaux transgeniques utilises pour tester des traitements potentiels relatifs a la maladie d'alzheimer
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
GB9210574D0 (en) 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1994006908A1 (fr) 1992-09-11 1994-03-31 The Regents Of The University Of California Animaux transgeniques possedant des genes de transduction lymphocytaire cibles
WO1994023049A2 (fr) 1993-04-02 1994-10-13 The Johns Hopkins University Introduction et expression de grandes sequences genomiques chez des animaux transgeniques
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
EP0679402B1 (fr) 1994-04-25 2003-09-10 Japan Science and Technology Corporation Gel hybride sécrétant une substance biologiquement active
US6028118A (en) 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
RU2198900C2 (ru) 1994-05-24 2003-02-20 Еда Рисерч энд Дивелопмент Ко., Лтд. Усовершенствованный сополимер-1 и способ его получения
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
JPH07316066A (ja) 1994-05-26 1995-12-05 Mochida Pharmaceut Co Ltd 創傷治癒剤
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
DK0871474T4 (da) 1994-12-29 2012-01-09 Ferring Int Ct Sa Fremstilling af human insulin
AUPN089295A0 (en) 1995-02-02 1995-03-02 International Diabetes Institute Treatment of diabetic neuropathy
US5631245A (en) 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
GB2310955A (en) 1996-03-06 1997-09-10 Central Research Lab Ltd Apparatus for blocking a dc component of a signal
JPH10265405A (ja) 1997-03-19 1998-10-06 Masaaki Nanbara インスリン含有の皮膚外用製剤
JP2002509855A (ja) 1997-10-16 2002-04-02 ズー、デグアン 皮膚、頭皮もしくは創傷への局所施用のための組成物及びその製造方法
AU3635099A (en) 1997-12-15 1999-07-26 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
IL139030A0 (en) 1998-04-17 2001-11-25 Angiogenix Inc Therapeutic angiogenic factors and methods for their use
US6376467B1 (en) 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
EP1098902A4 (fr) * 1998-07-23 2002-07-24 Yeda Res & Dev Traitement de maladies auto-immunes a l'aide du copolymere 1 et des copolymeres et peptides apparentes
ES2327301T3 (es) * 1998-09-25 2009-10-27 Yeda Research And Development Co., Ltd. Polipeptidos relacionados con el copolimero 1 para su uso como marcadores de pesos moleculares y para uso terapeutico.
US6096288A (en) 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
WO2000030628A2 (fr) 1998-11-20 2000-06-02 Genentech, Inc. Methode d'inhibition de l'angiogenese
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6541447B1 (en) 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
ATE358718T1 (de) * 2000-02-25 2007-04-15 Immunex Corp Integrin antagonisten
US20060258562A1 (en) 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
EP1383540B1 (fr) 2000-07-31 2009-04-29 Bar-Ilan University Methodes et compositions pharmaceutiques de cicatrisation de lesions
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US6673603B2 (en) 2000-09-01 2004-01-06 Modex Therapeutiques, S.A. Cell paste comprising keratinocytes and fibroblasts
US20020119914A1 (en) 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
US6750234B2 (en) 2001-03-08 2004-06-15 University Of Kentucky Research Foundation Methods for increasing leptin levels using nicotinic acid compounds
JP2002272831A (ja) 2001-03-14 2002-09-24 Fumio Kamiyama 創傷被覆用粘着性シート
JP2004532230A (ja) 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
AU2002319847A1 (en) 2001-05-23 2002-12-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) New nuclear receptor cofactors and related modulators
US6967018B2 (en) 2002-01-11 2005-11-22 Applied Genetic Technologies Corporation Adiponectin gene therapy
US7235062B2 (en) 2002-01-24 2007-06-26 Applied Medical Resources Corporation Surgical access device with floating gel seal
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
JP4668902B2 (ja) 2003-08-07 2011-04-13 ヒーラー リミテッド 創傷治癒を促進するための薬剤組成物及び方法
US7346787B2 (en) * 2004-12-07 2008-03-18 Intel Corporation System and method for adaptive power management
US7571295B2 (en) * 2005-08-04 2009-08-04 Intel Corporation Memory manager for heterogeneous memory control
NZ566083A (en) 2005-08-29 2012-11-30 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
WO2007075911A2 (fr) 2005-12-22 2007-07-05 Yale University Inhibition de la glycogene synthase kinase et procedes de traitement de maladies immunitaires ou autoimmunitaires inflammatoires
US9203086B2 (en) 2013-05-24 2015-12-01 The Boeing Company Thermally managed battery assembly
JP6149841B2 (ja) 2014-10-22 2017-06-21 トヨタ自動車株式会社 ハイブリッド自動車

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US4940660A (en) * 1985-11-25 1990-07-10 Wako Pure Chemical Industries Color developing method in clinical examinations
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5461030A (en) * 1991-02-01 1995-10-24 Life Medical Science, Inc. Compositions and methods for enhancing wound healing
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5770228A (en) * 1991-11-04 1998-06-23 Zymogenetics, Inc. Platelet derived growth factor gel formulation
US6737241B2 (en) * 1996-01-23 2004-05-18 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US5942487A (en) * 1996-11-29 1999-08-24 Senju Pharmaceutical Co., Ltd. Composition for treating cornea
US6319907B1 (en) * 1997-02-13 2001-11-20 Renovo Limited Wound healing
US6489306B2 (en) * 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6582713B2 (en) * 2000-04-06 2003-06-24 Univ. Of Colorado - Colorado Springs Compositions and methods for promoting wound healing
US20050054608A1 (en) * 2000-11-29 2005-03-10 Claire Linge Method of preventing or reducing scarring of human skin
US20080182780A1 (en) * 2000-11-29 2008-07-31 Claire Linge Method of Preventing or Reducing Scarring of Human Skin
US6841472B2 (en) * 2000-12-26 2005-01-11 Nec Electronics Corporation Semiconductor device and method of fabricating the same
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507431B2 (en) 2003-08-07 2013-08-13 Healor Ltd. Methods for accelerating wound healing by administration of a preadipocyte modulator or an adipocyte modulator
US20110021422A1 (en) * 2005-08-29 2011-01-27 Tamar Tennenbaum Method and compositions for prevention and treatment of diabetic and aged skin
US8367606B2 (en) 2005-08-29 2013-02-05 Healor Ltd. Method and compositions for prevention and treatment of diabetic and aged skin
US20100062048A1 (en) * 2006-05-02 2010-03-11 University Of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
US10583098B2 (en) * 2006-05-02 2020-03-10 Sung Lan Hsia Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
US8349793B2 (en) 2010-01-11 2013-01-08 Heal0r, Ltd. Method for treatment of inflammatory disease and disorder
WO2017053659A1 (fr) * 2015-09-23 2017-03-30 Khan Tapan K Méthodes pour la survie et la régénération de fibroblastes du derme à l'aide d'activateurs de la pkc
US11419830B2 (en) 2017-05-17 2022-08-23 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa

Also Published As

Publication number Publication date
EP2526952A1 (fr) 2012-11-28
RU2008138474A (ru) 2010-04-10
JP2013177436A (ja) 2013-09-09
HK1090843A1 (en) 2007-01-05
CA2532352A1 (fr) 2005-01-27
US8093211B2 (en) 2012-01-10
US20120076764A1 (en) 2012-03-29
EP2540301A3 (fr) 2013-04-10
RU2006104617A (ru) 2007-09-10
US20100167987A9 (en) 2010-07-01
AU2009225335A1 (en) 2009-11-05
EP2540301A2 (fr) 2013-01-02
AU2004257485B2 (en) 2010-07-01
US20080280816A1 (en) 2008-11-13
EP1648474A4 (fr) 2009-03-25
CN103751211A (zh) 2014-04-30
AU2004257485A1 (en) 2005-01-27
EP2526953A1 (fr) 2012-11-28
WO2005007072A3 (fr) 2005-05-12
EP1648474A2 (fr) 2006-04-26
RU2359694C2 (ru) 2009-06-27
EP2540302A1 (fr) 2013-01-02
EP1648474B1 (fr) 2013-09-04
JP5852051B2 (ja) 2016-02-03
US20090192074A1 (en) 2009-07-30
AU2009225335B2 (en) 2011-08-25
WO2005007072A2 (fr) 2005-01-27
RU2392959C1 (ru) 2010-06-27

Similar Documents

Publication Publication Date Title
US8093211B2 (en) Methods and pharmaceutical compositions for healing wounds
JP5385321B2 (ja) 創傷治療のための方法および薬学的組成物
US20060258562A1 (en) Methods and pharmaceutical compositions for healing wounds
AU2001284364A1 (en) Methods and pharmaceutical compositions for healing wounds
IL173148A (en) Use of insulin for the preparation of pharmaceutical compositions for healing wounds
US20100129332A1 (en) Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) Methods and pharmaceutical compositions of healing wounds
AU2011226776B2 (en) Methods and pharmaceutical compositions for healing wounds
IL154210A (en) Pharmaceutical compositions and uses thereof for healing wounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAR-ILAN UNIVERSITY, ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TENNENBAUM, TAMAR;SAMPSON, SANFORD;KUROKI, TOSHIO;AND OTHERS;REEL/FRAME:014423/0820;SIGNING DATES FROM 20030803 TO 20030814

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION